ArticleBritish journal of cancer2021
The risk of contralateral breast cancer: a SEER-based analysis.
Article in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Adjuvant endocrine therapy and risk of contralateral breast cancer: a systematic review and meta-analysis of observational studies.Cancer causes & control : CCC · 2025Pooled it
- Breast Cancer Outcomes From Ductal Carcinoma In Situ: A Population-Based Cohort Study.International journal of cancer · 2026Article
- Risk Stratification of Atypical Breast Lesions Diagnosed on Core Needle Biopsy: Toward Selective Surgical Excision.Annals of surgical oncology · 2026Article
- Risk Factors for Estrogen Receptor Subtype-Specific Contralateral Breast Cancer in Women Under Age 55 Years.International journal of cancer · 2026Article
- Effect of adjuvant endocrine therapy on recurrence and contralateral breast cancer in HR-positive DCIS after mastectomy.Breast (Edinburgh, Scotland) · 2026Observational
- Enhancing Early Detection of Contralateral Breast Cancer in Breast Cancer Survivors Using AI-Assisted Mammography.Annals of surgical oncology · 2026Article
- Overall and central adiposity and risk of contralateral breast cancer: The California Breast Cancer Survivorship Consortium.International journal of cancer · 2026Article
- Contralateral breast cancer after radiotherapy and hormone therapy in two cohorts of US breast cancer survivors.British journal of cancer · 2026Article
- Clinicopathological features and diagnostic intervals of second primary breast cancer following a prior malignancy: a single-center retrospective study.Frontiers in oncology · 2026Article
- Bilateral Primary Breast Cancer: Current Evidence and Future Perspectives.Breast cancer (Dove Medical Press) · 2026Review
- Article
- Oncolactation for Patients with Breast Cancer: Executive Summary from the American Society of Breast Surgeons.Annals of surgical oncology · 2025Review
- Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.Breast cancer research and treatment · 2025Observational
- Thyroid avoidance in treatment planning for breast cancer patients irradiated to the supraclavicular nodes.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Trends and survival benefits of bilateral breast-conserving surgery in patients with metachronous bilateral breast cancer.BMC women's health · 2025Article
- Misclassification of second primary and recurrent breast cancer in the surveillance epidemiology and end results registry.Cancer causes & control : CCC · 2025Article
- Recurrence Patterns and Long-Term Results After Curative Surgery for Patients With Breast Cancer.Annals of surgical oncology · 2025Article
- Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk.NPJ breast cancer · 2025Article
- Risk factors for second primary breast cancer by laterality, age, and race and ethnicity.Journal of the National Cancer Institute · 2025Article
- Breast cancer recurrence in relation to mode of detection: implications on personalized surveillance.Breast cancer research and treatment · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundWe sought to estimate the annual risk and 25-year cumulative risk of contralateral breast cancer among women with stage 0-III unilateral breast cancer.
methodsWe identified 812,851 women with unilateral breast cancer diagnosed between 1990 and 2015 in the SEER database and followed them for contralateral breast cancer for up to 25 years. Women with a known bilateral mastectomy were excluded. We calculated the annual risk of contralateral breast cancer by age at diagnosis, by time since diagnosis and by current age. We compared risks by ductal carcinoma in situ (DCIS) versus invasive disease, by race and by oestrogen receptor (ER) status of the first cancer.
resultsThere were 25,958 cases of contralateral invasive breast cancer diagnosed (3.2% of all patients). The annual risk of contralateral breast cancer over the 25-year follow-up period was 0.37% and the 25-year actuarial risk of contralateral invasive breast cancer was 9.9%. The annual risk varied to a small degree by age of diagnosis, by time elapsed since diagnosis and by current age. The 25-year actuarial risk was similar for DCIS and invasive breast cancer patients (10.1 versus 9.9%). The 25-year actuarial risk was higher for black women (12.7%) than for white women (9.7%) and was lower for women with ER-positive breast cancer (9.5%) than for women with ER-negative breast cancer (11.2%).
conclusionsWomen with unilateral breast cancer experience an annual risk of contralateral breast cancer ~0.4% per year, which persists over the 25-year follow-up period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.